Testosterone Cypionate vs Enclomiphene Citrate: Side-Effect Profile Head-to-Head

How These Two Drugs Work Differently

Testosterone cypionate delivers exogenous testosterone directly into circulation, bypassing the hypothalamic-pituitary-gonadal (HPG) axis entirely. The pituitary detects supraphysiologic androgen levels and shuts down luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion, which halts testicular sperm production within weeks 1.

Enclomiphene citrate takes the opposite approach. As the trans-isomer of clomiphene, it blocks estrogen receptors at the hypothalamus and pituitary, tricking the brain into producing more LH and FSH. The testes respond by manufacturing both testosterone and sperm. Kim et al. demonstrated that enclomiphene restored serum testosterone to eugonadal levels (average increase to ~450 ng/dL) while maintaining sperm concentrations above 20 million/mL in men with secondary hypogonadism 2.

This mechanistic split explains nearly every difference in their side-effect profiles. One drug replaces the signal. The other amplifies it.

Hematologic Side Effects: Polycythemia and Clotting Risk

Polycythemia is the most common laboratory abnormality with testosterone cypionate. The T-Trials consortium, which enrolled 790 men aged 65 and older with serum testosterone below 275 ng/dL, reported that hematocrit exceeded 54% in approximately 6% of testosterone-treated men compared to 1% on placebo over 12 months 1. Other registry data place the incidence between 5% and 14% depending on dose and route 3. A hematocrit above 54% increases blood viscosity and raises the risk of venous thromboembolism, stroke, and myocardial infarction. The Endocrine Society's 2018 guideline recommends checking hematocrit at 3 months, 6 months, and annually thereafter, with dose reduction or therapeutic phlebotomy if it exceeds 54% 4.

Enclomiphene does not introduce supraphysiologic androgen levels. The testosterone increase is more modest (typically reaching 400-550 ng/dL rather than 600-1 to 100 ng/dL with injections), and published trials have not identified polycythemia as a significant adverse event 2. This does not mean the risk is zero. Any rise in testosterone can stimulate erythropoiesis. But the magnitude of increase with enclomiphene is smaller, and the clinical signal for dangerous hematocrit elevations has not appeared in trials enrolling several hundred men.

Fertility and Reproductive Side Effects

This is the sharpest dividing line between the two drugs.

Testosterone cypionate suppresses intratesticular testosterone production by eliminating LH. Sperm counts drop to azoospermic or severely oligospermic levels in 65-90% of men within 3-6 months of starting therapy 5. Recovery after discontinuation is variable. A WHO-sponsored study of testosterone-based contraception found that 67% of men recovered to 20 million sperm/mL by 6 months and 90% by 12 months, but a subset required 24 months or longer 5. For men who want children, this is not a side effect. It is a contraindication.

Enclomiphene preserves spermatogenesis by design. Kim et al. showed that men on enclomiphene 25 mg daily maintained mean sperm concentrations of 36.3 million/mL at 12 months, compared to a decline toward oligospermia in a testosterone gel comparison arm 2. The American Urological Association's 2018 guideline on male infertility lists SERMs as the preferred pharmacologic option for hypogonadal men who wish to preserve fertility 6.

Dr. Robert Brannigan, Professor of Urology at Northwestern, has stated: "Any man of reproductive age who is considering testosterone therapy needs to understand that exogenous testosterone is a male contraceptive. If fertility is a priority, SERMs or hCG should be the first conversation" 6.

Cardiovascular Risk

The FDA added a black-box warning to all testosterone products in 2015 after observational studies suggested increased rates of myocardial infarction and stroke in older men and men with pre-existing cardiovascular disease 7. The TRAVERSE trial (N=5,246), published in 2023, provided more definitive data: testosterone replacement in men aged 45-80 with hypogonadism and cardiovascular risk factors did not increase the composite rate of major adverse cardiovascular events (MACE) compared to placebo (hazard ratio 0.96 to 95% CI 0.78-1.17) over a mean follow-up of 33 months 8. The MACE signal appears neutral, though the trial did show higher rates of atrial fibrillation, acute kidney injury, and pulmonary embolism in the testosterone arm.

No large cardiovascular outcome trial exists for enclomiphene. Its cardiovascular safety profile is extrapolated from the broader SERM class. Tamoxifen and raloxifene carry their own thrombotic risks in women, but male SERM data is limited. Short-term trials of enclomiphene (up to 12 months) have not flagged excess cardiovascular events 2, but the sample sizes are too small to draw reliable conclusions. The absence of evidence is not evidence of absence.

Estrogenic and Anti-Estrogenic Side Effects

Testosterone cypionate aromatizes to estradiol via the aromatase enzyme, particularly in adipose tissue. Elevated estradiol can produce gynecomastia (reported in 10-25% of TRT users depending on dose and body composition), nipple tenderness, water retention, and mood fluctuation 4. Clinicians often add anastrozole to manage estradiol levels, though the Endocrine Society does not recommend routine aromatase inhibitor co-prescription 4.

Enclomiphene creates a different estrogen problem. By blocking hypothalamic estrogen receptors, it disrupts estrogen-mediated feedback without lowering circulating estradiol. In fact, estradiol levels typically rise modestly because the increase in LH drives more testicular testosterone production, and more testosterone means more substrate for aromatization. The clinical consequence is that men on enclomiphene rarely develop gynecomastia (the breast tissue receptor is not being stimulated in the same way), but they may experience hot flashes, a side effect that results from central estrogen receptor blockade. Hot flashes occur in approximately 5-10% of men on SERMs 9.

Visual Disturbances

This side effect is nearly exclusive to the SERM class. Clomiphene citrate (the racemic mixture of enclomiphene and zuclomiphene) has long been associated with blurred vision, floaters, light sensitivity, and rare cases of optic neuropathy. The zuclomiphene isomer is considered the primary culprit due to its longer half-life and estrogenic activity 9.

Enclomiphene, as the isolated trans-isomer, appears to carry a lower incidence of visual symptoms than racemic clomiphene. Phase II data reported visual complaints in approximately 2-3% of enclomiphene-treated men, compared to 5-10% with racemic clomiphene 2. The standard clinical recommendation remains the same: discontinue the drug immediately if visual changes occur, as some cases of clomiphene-associated retinal damage are irreversible.

Testosterone cypionate does not cause visual disturbances.

Mood, Libido, and Neuropsychiatric Effects

Both drugs raise serum testosterone, but the subjective experience can differ. The T-Trials found that testosterone gel improved sexual desire scores (measured by PDQ-Q4) by 0.58 points more than placebo on a 1-5 scale (P<0.001) and increased sexual activity frequency 1. Mood improvements were modest and did not reach statistical significance in men without baseline depressive symptoms 10.

Enclomiphene's effect on libido is less well characterized. Open-label studies report patient-reported improvements in energy and sexual function, but placebo-controlled data on validated sexual function questionnaires are sparse. Anecdotal reports from clinical practice suggest that some men who switch from exogenous testosterone to enclomiphene notice a reduction in libido or subjective "well-being," possibly because peak testosterone levels on enclomiphene are lower than on injections, or because of central estrogen receptor blockade affecting mood pathways.

On the negative side, testosterone cypionate at supraphysiologic doses can cause irritability, aggression, and mood swings. Sleep apnea worsening is another recognized risk. The Endocrine Society lists obstructive sleep apnea as a relative contraindication to testosterone therapy 4.

Hepatic and Metabolic Effects

Oral androgens (17-alpha-alkylated testosterone) are hepatotoxic, but testosterone cypionate is not 17-alpha-alkylated and is administered parenterally. Liver toxicity from injectable testosterone esters is rare. Lipid effects are the more relevant metabolic concern: testosterone cypionate typically lowers HDL cholesterol by 5-15% without significantly affecting LDL 4.

Enclomiphene has not been associated with liver enzyme elevations in published trials lasting up to 12 months. Its effect on lipid panels is not well characterized in men, though SERMs generally have a favorable effect on LDL in women (raloxifene lowers LDL by approximately 10%). Whether this translates to men on enclomiphene is unknown.

Prostate Safety

Testosterone cypionate triggers PSA monitoring requirements. The T-Trials reported a small but statistically significant increase in PSA (mean increase of 0.5 ng/mL) over 12 months in testosterone-treated men compared to placebo 1. A PSA increase above 1.4 ng/mL from baseline or an absolute value exceeding 4.0 ng/mL warrants urologic referral per Endocrine Society guidelines 4. The TRAVERSE trial did not find a significant increase in prostate cancer incidence over 33 months 8.

Enclomiphene raises testosterone within the physiologic range, and the PSA effect appears proportionate to the testosterone increase. No published trial has reported a clinically significant PSA signal with enclomiphene, but prostate monitoring is still reasonable for any therapy that raises androgen levels.

Who Should Choose Which Drug

The decision between testosterone cypionate and enclomiphene is not purely about side effects. It is about clinical context.

Testosterone cypionate is the stronger drug for symptomatic relief. It delivers predictable serum levels, has decades of safety data, and reliably improves sexual function, body composition, and bone density in hypogonadal men 1. The trade-offs are real: fertility suppression, hematocrit monitoring, HDL reduction, and a daily or weekly injection schedule.

Enclomiphene is the rational first-line choice for younger men with secondary hypogonadism who want to preserve fertility. Its side-effect profile is lighter on paper, but the drug remains investigational in the United States, the evidence base is thinner, and long-term safety data beyond 12 months is limited 2.

The Endocrine Society's 2018 guideline recommends testosterone therapy for confirmed hypogonadism with symptoms, while noting that SERMs are an off-label alternative when fertility preservation is desired 4.

Dr. Shalender Bhasin, lead investigator of the T-Trials, has noted: "The choice between exogenous testosterone and agents that stimulate endogenous production should be individualized based on the patient's reproductive goals, comorbidities, and the specific hypogonadal phenotype" 1.

Monitoring Requirements Compared

Men on testosterone cypionate need hematocrit checked at baseline, 3 months, 6 months, and annually. PSA and digital rectal exam are recommended at 3-6 months and annually in men over 40. Lipid panels and estradiol levels should be reviewed at least annually. Bone density testing (DEXA) is appropriate if the indication is osteoporosis prevention 4.

Men on enclomiphene require fewer mandatory labs. Serum testosterone, LH, FSH, and estradiol at baseline and 3 months confirm the drug is working. A semen analysis is appropriate if fertility preservation is the primary goal. Hematocrit monitoring is reasonable but not mandated by any guideline given the low observed risk. Any visual symptoms require immediate ophthalmologic referral.

The monitoring gap is significant. Testosterone cypionate creates more lab work, more clinic visits, and more clinical decision points. For men who dislike frequent blood draws, this is a practical consideration alongside the pharmacologic ones.

Baseline hematocrit above 50%, untreated severe sleep apnea, active desire for fertility within 6-12 months, or a history of venous thromboembolism should all prompt a clinician to consider enclomiphene (or another SERM/hCG) before testosterone cypionate 4.